venous thromboembolism. - **Special populations:** Anti-factor Xa levels are\*\*\*\* especially useful in cases of patients with obesity, patients with renal insufficiency, patients who are underweight, and pregnant patients to help ensure therapeutic levels.[10] - **Timing of level draws:** Levels should be checked 3 to 5 hours after the third dose to ensure accuracy of interpretation.[10] ## Enhancing Healthcare Team Outcomes When interpreting abnormal blood clotting study results, it's essential to consider the clinical context, medical history, and potential contributing factors. For example, a patient on anticoagulant therapy may have intentionally prolonged PT and INR values. Similarly, a patient with liver disease may exhibit abnormal PT and PTT due to impaired synthesis of clotting factors. Addressing abnormal values involves a multidisciplinary approach. In collaboration with other specialists, a hematologist can determine the underlying cause and develop a tailored treatment plan. This may include administering clotting factor concentrates, adjusting anticoagulant medications, or addressing the specific condition contributing to the abnormal clotting profile. Blood clotting studies provide valuable information about an individual's coagulation status, helping clinicians assess the risk of bleeding or thrombosis. Understanding the normal and abnormal values of PT, PTT, INR, and D-dimer is crucial for accurate interpretation and effective management of coagulation disorders. Regular monitoring and collaboration between healthcare professionals are key to ensuring optimal patient care and preventing complications associated with abnormal clotting. ## Review Questions - [Access free multiple choice questions on this topic.](https://www.statpearls.com/account/trialuserreg/?articleid=161112&utm_source=pubmed&utm_campaign=reviews&utm_content=161112) - [Comment on this article.](https://www.statpearls.com/articlelibrary/commentarticle/161112/?utm_source=pubmed&utm_campaign=comments&utm_content=161112) ## References 1. Blennerhassett R, Favaloro E, Pasalic L. Coagulation studies: achieving the right mix in a large laboratory network. Pathology. 2019 Dec;51(7):718-722. \[[PubMed: 31668405](https://pubmed.ncbi.nlm.nih.gov/31668405)\] 2. Dorgalaleh A, Favaloro EJ, Bahraini M, Rad F. Standardization of Prothrombin Time/International Normalized Ratio (PT/INR). Int J Lab Hematol. 2021 Feb;43(1):21-28. \[[PubMed: 32979036](https://pubmed.ncbi.nlm.nih.gov/32979036)\] 3. Feinbloom D, Freed JA, Carbo A, Jung Y, Adra M, Herzig SJ. Incidence and risk factors for PTT prolongation in patients receiving low-dose unfractionated heparin thromboprophylaxis. J Thromb Thrombolysis. 2021 Jul;52(1):331-337. \[[PubMed: 33006065](https://pubmed.ncbi.nlm.nih.gov/33006065)\] 4. Toulon P, Smahi M, De Pooter N. APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation. J Thromb Haemost. 2021 Aug;19(8):2002-2006. \[[PubMed: 33555096](https://pubmed.ncbi.nlm.nih.gov/33555096)\] 5. Weitz JI, Fredenburgh JC, Eikelboom JW. A Test in Context: D-Dimer. J Am Coll Cardiol. 2017 Nov 07;70(19):2411-2420. \[[PubMed: 29096812](https://pubmed.ncbi.nlm.nih.gov/29096812)\] 6. Ignjatovic V. Activated partial thromboplastin time. Methods Mol Biol. 2013;992:111-20. \[[PubMed: 23546708](https://pubmed.ncbi.nlm.nih.gov/23546708)\] 7. Chornenki NLJ, Fralick M, Sholzberg M. International normalized ratio